Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $155.00 short put and a strike $145.00 long put offers a potential 23.92% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $155.00 by expiration. The full premium credit of $1.93 would be kept by the premium seller. The risk of $8.07 would be incurred if the stock dropped below the $145.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is at 58.82 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
TripAdvisor, Yandex Among IBD 50 Leaders Reporting
Sat, 19 Oct 2013 12:02:00 GMT
Investor's Business Daily – TripAdvisor, Yandex Among IBD 50 Leaders Reporting
Stocks at 1-year highs: Amgen, Starbucks & more
Fri, 18 Oct 2013 16:48:00 GMT
CNBC – There are over 100 S&P 500 stocks soaring to new 52-week highs. The FMHR traders take their positions.
Fri, 18 Oct 2013 11:32:00 GMT
Forbes – Actual bubble, not to be confused with the metaphorical bubble discussed at left. (Photo credit: Wikipedia) For me, one glance was all it took. Looking at my colleague's computer from across the room, I could see that this pre-IPO company's lead oncology asset — presumably the driving force behind this white-hot offering […]
Interesting CELG Put And Call Options For November 22nd
Thu, 17 Oct 2013 15:45:00 GMT
Forbes – Investors in Celgene Corp. (NASD: CELG) saw new options become available today, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CELG options chain for the new November 22nd contracts and identified one put and one call contract of particular interest. The […]
Encouraging Data Published on CELG's Abraxane
Thu, 17 Oct 2013 15:00:06 GMT
Zacks – Celgene announced that encouraging data from a phase III study on Abraxane was published.
Also on Market Tamer…
Follow Us on Facebook